The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapies

ChangMoo Kang, Michele L. Babicky, Andrew M. Lowy

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Pancreatic cancer remains a devastating disease with a mortality rate that has not changed substantially in decades. Novel therapies are therefore desperately needed. The RON receptor tyrosine kinase has been identified as an important mediator of KRAS oncogene addiction and is overexpressed in the majority of pancreatic cancers. Preclinical studies show that inhibition of RON function decreases pancreatic cancer cell migration, invasion, and survival and can sensitize pancreatic cancer cells to chemotherapy. This article reviews the current state of knowledge regarding RON biology and pancreatic cancer and discusses its potential as a therapeutic target.

Original languageEnglish
Pages (from-to)183-189
Number of pages7
JournalPancreas
Volume43
Issue number2
DOIs
Publication statusPublished - 2014 Mar 1

Fingerprint

Receptor Protein-Tyrosine Kinases
Pancreatic Neoplasms
Therapeutics
Oncogenes
Cell Movement
Cell Survival
rice bran saccharide
Drug Therapy
Mortality

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology

Cite this

@article{7b8dcf65e9bd460cbafad4fb4a08aa7c,
title = "The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapies",
abstract = "Pancreatic cancer remains a devastating disease with a mortality rate that has not changed substantially in decades. Novel therapies are therefore desperately needed. The RON receptor tyrosine kinase has been identified as an important mediator of KRAS oncogene addiction and is overexpressed in the majority of pancreatic cancers. Preclinical studies show that inhibition of RON function decreases pancreatic cancer cell migration, invasion, and survival and can sensitize pancreatic cancer cells to chemotherapy. This article reviews the current state of knowledge regarding RON biology and pancreatic cancer and discusses its potential as a therapeutic target.",
author = "ChangMoo Kang and Babicky, {Michele L.} and Lowy, {Andrew M.}",
year = "2014",
month = "3",
day = "1",
doi = "10.1097/MPA.0000000000000088",
language = "English",
volume = "43",
pages = "183--189",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapies. / Kang, ChangMoo; Babicky, Michele L.; Lowy, Andrew M.

In: Pancreas, Vol. 43, No. 2, 01.03.2014, p. 183-189.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapies

AU - Kang, ChangMoo

AU - Babicky, Michele L.

AU - Lowy, Andrew M.

PY - 2014/3/1

Y1 - 2014/3/1

N2 - Pancreatic cancer remains a devastating disease with a mortality rate that has not changed substantially in decades. Novel therapies are therefore desperately needed. The RON receptor tyrosine kinase has been identified as an important mediator of KRAS oncogene addiction and is overexpressed in the majority of pancreatic cancers. Preclinical studies show that inhibition of RON function decreases pancreatic cancer cell migration, invasion, and survival and can sensitize pancreatic cancer cells to chemotherapy. This article reviews the current state of knowledge regarding RON biology and pancreatic cancer and discusses its potential as a therapeutic target.

AB - Pancreatic cancer remains a devastating disease with a mortality rate that has not changed substantially in decades. Novel therapies are therefore desperately needed. The RON receptor tyrosine kinase has been identified as an important mediator of KRAS oncogene addiction and is overexpressed in the majority of pancreatic cancers. Preclinical studies show that inhibition of RON function decreases pancreatic cancer cell migration, invasion, and survival and can sensitize pancreatic cancer cells to chemotherapy. This article reviews the current state of knowledge regarding RON biology and pancreatic cancer and discusses its potential as a therapeutic target.

UR - http://www.scopus.com/inward/record.url?scp=84894449126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894449126&partnerID=8YFLogxK

U2 - 10.1097/MPA.0000000000000088

DO - 10.1097/MPA.0000000000000088

M3 - Review article

VL - 43

SP - 183

EP - 189

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 2

ER -